Vered Stearns, MD
Professor of Oncology
Co-Director of the Breast Cancer Program
Johns Hopkins University School of Medicine
Dr. Stearns joined the Johns Hopkins faculty in 2002 and is best known for her ground-breaking work on the pharmacogenetics of tamoxifen and the use of biomarkers to implement new interventions for breast cancer treatment and prevention.
Her research focuses on agents that target epigenetic modifications in breast cancer and gene methylation as a prognostic and predictive marker in breast cancer and she is internationally recognized for her research in improving therapeutic options for women who suffer vasomotor symptoms as well as elucidating the role of pharmacogenetics and tamoxifen-related outcomes.
Originally from Israel, Dr. Stearns
started a 7-year medical school program at the Tel-Aviv University
in 1985 through an academic reserve program.
She transferred to the University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, at Camden, New Jersey, as a third year medical student where she was awarded her medical degree in 1992.
internal medicine residency and fellowship training at Georgetown University
trained under some of the most influential leaders in translational breast cancer research.
During that time, Vered
was one of the first investigators in the world to perform biomarker studies with novel therapies in the pre-surgical setting.
As a clinician, Dr. Stearns sees patients as an attending physician on the inpatient service and for outpatient consultations.
also supervises fellows, residents, and medical students in outpatient and inpatient services.
also leads an active research team at the Johns Hopkins Kimmel Cancer Center
and helped build the multidisciplinary breast cancer program.
was also instrumental in building the multidisciplinary translational research team and the infrastructure for innovative early clinical trials.